title: Are routine tuberculosis programme data suitable to report on antiretroviral therapy use of HIV-infected tuberculosis patients?
abstract: BACKGROUND
  Antiretroviral therapy (ART) is lifesaving for HIV-infected tuberculosis (TB) patients. ART-use by these patients lag behind compared to HIV-testing and co-trimoxazole preventive therapy. TB programmes provide the data on ART-use by HIV-infected TB patients, however often the HIV services provide the ART. We evaluated whether the data on ART-use in the TB register were complete and correct. The timing of ART initiation was evaluated to assess whether reporting on ART-use could have happened with the TB case finding reporting. We collected data on TB treatment, HIV testing and ART for adult TB cases in 2007 from three TB clinics in Manica Province, Mozambique. These data on use of ART from TB registers were compared with those from the HIV services.
  
  
  RESULTS
  Of 628 patients included, 504 (81%) were tested and of these 356 (71%) were HIV-infected. Of the co-infected patients, 81% registered with the HIV services in the same facility. The TB register was correct on ART-use in 73% of co-infected cases and complete in 74%. Information on ART-use could have been reported with the TB case finding reports in 56% of co-infected patients.
  
  
  CONCLUSIONS
  The TB register is reasonably correct and complete on ART-use. However, the HIV patient record seems a much better source to provide this information. Reporting on ART-use at the end of the quarter in which TB treatment starts provides the programme with timely but incomplete information. A more complete but less timely picture is available after a year.
authors: Health Alliance International, Technical Assistance Unit, Maputo, Mozambique. brouwer.miranda@gmail.com
authors: Miranda
authors: M
authors: Brouwer
authors: Paula Samo
authors: PS
authors: Gudo
authors: Chalice Mage
authors: CM
authors: Simbe
authors: Paula
authors: P
authors: Perdigão
authors: Frank
authors: F
authors: van Leth
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D014376:Tuberculosis / Q000150:complications*
chemical_list: D019380:Anti-HIV Agents